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Case Report
Tuberculoid Leprosy Masquerading as Erythema
Induratum
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Erythema Induratum (EI) is a relatively rare dermatologic disorder affecting subcutaneous
fat tissue, which is often associated with Mycobacterium tuberculosis. This report details
the presentation, diagnosis and management in a 70-year-old female who presented with a
painful erythematous annular rash at the clinic. The rash was later diagnosed as EI associated with Mycobacterium leprae, one rarely seen in literature.
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Discussion

EI is a rare form of panniculitis that typically presents as a recurrent grouping of tender
nodules and plaques on the posterior aspect of the lower legs. Although EI is considered
idiopathic in most cases, it can be associated with M. leprae. Given the atypical presentation
of a rash, a biopsy was done. It showed epithelioid granulomatous dermatitis with lobar
panniculitis. A DNA polymerase chain reaction (PCR) was also sent and revealed the presence of M. leprae. Treatment of EI without association with M. leprae includes potassium
iodide, non-steroidal anti-inflammatory drugs (NSAIDs), rest, elevation, compression and, in
severe cases, systemic immunosupressives. If tuberculoid leprosy is confirmed, the attending physician is encouraged to consult the infectious disease department as treatment
varies with presentation.

Conclusions

This case details the diagnosis and management involved in a case of tuberculoid leprosy
masquerading as EI. Management of the EI involved NSAIDs and potassium iodide. The
leprosy was treated with dapsone and rifampin in conjunction with an infectious disease
consultation. Our case highlights the importance of relying on a strong clinical suspicion
based on a patient’s social history in order to diagnose rare entities accurately.
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Background

Erythema Induratum (EI) is an inflammatory
disorder affecting subcutaneous fat tissue and
is interchangeably known as nodular vasculitis
when it is not associated with tuberculosis. EI
published cases are rarely seen throughout the
world. The incidence and prevalence of EI has
not been reported. Women ages 13 through
66 (mean age 37 and median age 56) are most
commonly affected by EI.1 Leprosy, which is
caused by Mycobacterium leprae and Mycobacterium lepromatosis, is an infection involving

the skin and peripheral nerves. There were 0.2
cases per 10,000 people worldwide in 2015 with
a majority of cases reported from developing
countries.2 This case report will detail the presentation, diagnosis and management of a case
of EI associated with tuberculoid leprosy.

Case Presentation

A 70-year-old Caucasian female with a medical history of type 2 diabetes mellitus, hypertension and hypothyroidism came into our
dermatology clinic presenting with a painful
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Figure 1. Photographs of the rash as seen on initial visit located in the right (A) lateral leg/foot
and (B) anterior foot. Markings represent punch biopsy sites.
rash located on the right lateral leg and right
anterior foot. The rash had been present for
three weeks and was unresponsive to topical
nystatin cream and doxycycline. She denied
recent travel or any interactions with armadillos. Her medications included low dose aspirin,
a multivitamin, fish oil, levothyroxine, lisinopril
and metoprolol tartate. At the initial visit, the
rash was described as erythematous annular
patches/plaques with a trailing scale distributed on the right foot and right lateral lower leg.
Differential diagnoses at that time included erythema annulare centrifugum, annular urticaria, erythema chronicum migrans, tinea, erythema nodosum and erythema induratum. Two,
millimeter punch biopsies were taken from the
right foot and right lateral lower leg. (Figures
1A and 1B) A prescription for 0.1% triamcinolone
acetodine topical ointment and non-steroidal
anti-inflammatories (NSAIDs) were given as
empiric treatment.

The following day, histopathology from both
biopsy sites showed epithelioid granulomatous
dermatitis with lobular panniculitis. (Figure
2) Periodic acid-Schiff (PAS) and Fite special
stains for fungus and mycobacteria were negative. The differential diagnosis was narrowed to
Darier-Roussy’s sarcoid and erythema induratum. Due to suspicion of leprosy, the tissue
block was sent for M. leprae and M. lepromatosis DNA polymerase chain reaction (PCR) tests,
but the results were not expected for several
weeks.
The patient returned to the clinic one week
later and had a hepatitis panel, an interferon-gamma release assay, and a thyroid stimulating hormone (TSH) test ordered. She was
prescribed potassium iodide 130 mg to take
three times a day (TID) for 21 days for the
treatment of EI and NSAIDs as needed for
pain. Laboratory tests were negative for tuber-

Figure 2. Pathology slide read as epithelioid granulomatous dermatitis with lobular panniculitis.
Differential diagnosis included Darier-Roussy’s sarcoid and erythema induratum.
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Figure 3. Follow up approximately 3 months after initial visit for rash, after potassium iodide and
topical triamcinolone treatment, located in the right (A) lateral leg/foot and (B) anterior foot.
culosis, hepatitis A, B and C. Her TSH was within normal range. The patient’s potassium iodide
was increased to 520 mg from the prior 390
mg daily. The patient reported that her pain
improved, and the NSAIDs were discontinued.
Physical examination noted residual erythema.
At her 7-week follow-up, the patient reported
that her EI was significantly better and less
painful. Her physical examination noted residual
erythema without any swelling or tenderness.
She reported completing the initial course
of potassium iodide. She was given another
course of potassium iodide 260 mg TID for one
week with subsequent taper over several weeks
to decrease the risk of altering thyroid function.
Approximately 10 weeks after the initial visit,
PCR results revealed the presence of M. leprae,
confirming a diagnosis of tuberculoid lepro-

sy-induced EI. At this point, the patient had asymptomatic post-inflammatory hyperpigmentation without any evidence of nerve damage.
(Figures 3A and 3B) Upon further questioning,
the patient reported that she often gardens
and has noticed armadillos in her yard. However, she denied any direct contact. She was
referred to the infectious disease department
and started on dapsone 100 mg and rifampin
600 mg for 6 to 12 months for tuberculoid leprosy with intact cell-mediated immunity. Her
EI showed continued improvement one month
into treatment with dapsone and rifampin.
(Figures 4A and 4B) The state health officials
were notified.

Discussion

EI is a rare form of panniculitis with female
preponderance that typically presents as recurrent crops of tender, violaceous nodules and
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Figure 4. Rash, after 1 month into treatment with dapsone and rifampin, located in the right (A)
lateral leg/foot and (B) posterior leg.
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plaques on the posterior aspect of the lower
legs with or without ulcerations.3 In most cases,
no inciting factor can be identified, but it can
be associated with M. leprae infection. The
most recent date that leprosy was recorded in
the United States (US) was 2015. There were
178 new cases that year with a vast majority of
them being in individuals who immigrated from
developing countries.4 The only known reservoirs of M. leprae are humans and wild armadillos in the southern part of the US. Given the
atypical presentation of EI in our patient and
the fact that she lived in rural Florida, which
is known to be inhabited by armadillos, a PCR
test was used to diagnose tuberculoid leprosy
causing EI. The PCR test for M. leprae is highly
specific but has relatively variable sensitivity
ranging from 34% to 90%.5 Tuberculoid leprosy
is associated with permanent nerve damage.
Thus, clinical suspicion is critical for management. Treatment of EI without association with
M. leprae includes potassium iodide, NSAIDs,
rest, elevation, compression and, in severe cases, systemic immunosuppressives.6-8 If tuberculoid leprosy is confirmed, it is imperative that
local health officials are notified. The treatment
regimen for tuberculoid leprosy with intact
cell-mediated immunity consists of dapsone
and rifampin in conjunction with an infectious
disease consult.
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